ATOSSA THERAPEUTICS, INC. (ATOS) Form 8-K — Aug 7, 2026
Atossa Therapeutics reported a second quarter 2026 net loss of $8.5 million on total operating expenses of $8.7 million, roughly flat versus the prior-year quarter's $9.0 million in operating expenses. Cash and equivalents fell to $26.1 million at June 30, 2026 from $41.3 million at year-end 2025. The company completed enrollment as of June 30, 2026 in its EVANGELINE Phase 2 trial of (Z)-endoxifen plus goserelin in premenopausal women with ER+/HER2- breast cancer. It also highlighted new conference data and peer-reviewed publications supporting (Z)-endoxifen in Duchenne Muscular Dystrophy, McCune-Albright Syndrome, and ESR1-mutated breast cancer.
Key figures
- Total Assets
- 32281000
- Cash Position
- 26094000
- Gross Proceeds
- 4500000
- Shares Outstanding
- 9979298
- Cash dec 31 2025 usd
- 41299000
- Offering shares sold
- 1363637
- Prv market sale range
- $100-$220 million (disclosed PRV sales, last 18-24 months)
- Total liabilities usd
- 5451000
- Q2 2026 ga expenses usd
- 3797000
- Q2 2026 rd expenses usd
- 4897000
- Stockholders equity usd
- 26830000
- Interest income q2 2026 usd
- 227000
- Weighted avg shares q2 2026
- 8908511
- Q2 2025 operating expenses usd
- 9040000
- Q2 2026 operating expenses usd
- 8694000
- Shares outstanding dec 31 2025
- 8611361
- Six month 2026 operating expenses usd
- 18564000
- Offering potential warrant proceeds usd
- 12000000
- Offering total potential gross proceeds usd
- 16500000
Price after filing
Close on the filing date to close N calendar days later (from $2.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.